GoodRx Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GoodRx Holdings, Inc. on March 14, 2024, covering events occurring on March 12 and March 13, 2024. The filing addresses significant changes to executive compensation and Board composition.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation adjustments:
- Equity Grants: Interim CEO Scott Wagner received a nonqualified stock option and a restricted stock unit (RSU) award, each valued at $4,000,000.
- Base Salary Bonus: Mr. Wagner is now eligible for an annual cash incentive bonus targeted at 100% of his annual base salary.
- Severance: Revised severance includes 12 months of base salary, a pro-rated bonus, and 12 months of COBRA coverage upon qualifying termination.
Material Changes
The filing details two primary material changes:
- Executive Employment Amendment: Scott Wagner's employment agreement was amended to extend the term from a fixed end date of April 25, 2024, to an indefinite term. The amendment also clarifies that the appointment of a permanent CEO or Mr. Wagner's subsequent termination will not constitute "good reason" for resignation.
- Board Resignations: Two directors resigned from the Board of Directors:
- Adam Karol resigned effective March 22, 2024.
- Stephen LeSieur resigned effective March 14, 2024.
Outlook, Risks, and Management Commentary
Management stated that the resignations of Mr. Karol and Mr. LeSieur were not the result of any disagreement with the Company regarding operations, policies, or practices. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the standard disclosures regarding the new employment terms.
Investor Verification Checklist
- Verify the vesting schedule for the $8,000,000 in total equity awards granted to Scott Wagner (monthly installments starting May 8, 2024).
- Confirm the Company's timeline and process for appointing a permanent Chief Executive Officer to replace the Interim CEO.
- Review the impact of the two director resignations on Board committee composition and quorum.
- Check subsequent filings for the specific performance goals tied to Mr. Wagner's 100% target bonus.